Research Article| Volume 12, ISSUE 4, P508-514, May 2021

Download started.


Disparities in treatment patterns and outcomes among younger and older adults with newly diagnosed multiple myeloma: A population-based study

Published:October 24, 2020DOI:



      Multiple myeloma, a cancer of older adults, has seen significant improvement in therapeutic options over the past two decades. Uncovering disparities in treatment patterns and outcomes is imperative in order to ensure older adults, who are underrepresented in clinical trials, are benefitting from these advances.


      Adults with newly diagnosed multiple myeloma (NDMM) were identified using linked provincial administrative databases between 2007 and 2017 in Ontario, Canada. Trends in rate of no treatment, novel drug and autologous stem cell transplant (ASCT) usage was evaluated within one year following diagnosis along with the associated early mortality (<12 months) for the aforementioned cohorts among younger (≤65 years) and older adults (>65 years) with NDMM.


      A total of 8841 adults with NDMM were identified. Rates of no treatment decreased in both age groups during the study period; however still remain considerably high among older patients (from 34.9% in 2007 to 27.4% in 2017) with high associated early mortality in the older untreated group (54.1% 1 yr mortality over study period). Despite increased usage of novel drugs in both age groups, early mortality decreased among younger patients utilizing novel drugs (16.1% to 5.6%) but remained high and stagnant in older patients using novel drugs (18.2% 1 yr mortality over study period). ASCT utilization increased in both age groups during the study period with decreasing early mortality among older patients undergoing ASCT (from 26.3% in 2007 to 1.1% in 2017).


      While several improvements have been made, rates of no treatment and early mortality among patients not treated and those started on novel drugs remains a concern in older adults with NDMM.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Geriatric Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Swerdlow S.H.C.E.
        • Harris N.L.
        • Jaffe E.S.
        • Pileri S.A.
        • Stein H.
        • et al.
        Lyon, France: IARC press; 2008. WHO classification of tumours of haematopoietic and lymphoid tissues.
        IARC Press, Lyon, France2008
      1. Altekruse S.F.K.C. Krapcho M. Neyman N. Aminou R. Waldron W. SEER cancer statistics review, 1975-2007. National Cancer Institute, Bethesda, MD2010
        • San Miguel J.F.
        • Schlag R.
        • Khuageva N.K.
        • et al.
        Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
        N Engl J Med. 2008 Aug 28; 359: 906-917
        • Benboubker L.
        • Dimopoulos M.A.
        • Dispenzieri A.
        • et al.
        Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
        N Engl J Med. 2014 Sep 04; 371: 906-917
        • Facon T.
        • Kumar S.K.
        • Plesner T.
        • et al.
        Phase 3 randomized study of daratumumab plus lenalidomide and dexamethasone (D-Rd) Versus lenalidomide and dexamethasone (Rd) in patients with newly diagnosed multiple myeloma (NDMM) ineligible for transplant (MAIA).
        Blood. 2018; 132 (LBA-2-LBA-2)
        • Kristinsson S.Y.
        • Anderson W.F.
        • Landgren O.
        Improved long-term survival in multiple myeloma up to the age of 80 years.
        Leukemia. 2014 Jun; 28: 1346-1348
        • Fonseca R.
        • Abouzaid S.
        • Bonafede M.
        • et al.
        Trends in overall survival and costs of multiple myeloma, 2000-2014.
        Leukemia. 2017 Sep; 31: 1915-1921
        • Kristinsson S.Y.
        • Landgren O.
        • Dickman P.W.
        • et al.
        Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003.
        J Clin Oncol. 2007 May 20; 25: 1993-1999
        • Brenner H.
        • Gondos A.
        • Pulte D.
        Recent major improvement in long-term survival of younger patients with multiple myeloma.
        Blood. 2008 Mar 1; 111: 2521-2526
        • Blimark C.H.
        • Turesson I.
        • Genell A.
        • et al.
        Outcome and survival of myeloma patients diagnosed 2008–2015. Real-world data on 4904 patients from the Swedish myeloma registry.
        Haematologica. 2018; 103: 506
        • Turesson I.
        • Bjorkholm M.
        • Blimark C.H.
        • et al.
        Rapidly changing myeloma epidemiology in the general population: increased incidence, older patients, and longer survival.
        Eur J Haematol. 2018; 101 (2018/08/01): 237-244
        • Costa L.J.
        • Brill I.K.
        • Omel J.
        • et al.
        Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States.
        Blood Adv. 2017 Jan 10; 1: 282-287
        • Schaapveld M.
        • Visser O.
        • Siesling S.
        • et al.
        Improved survival among younger but not among older patients with multiple myeloma in the Netherlands, a population-based study since 1989.
        Eur J Cancer. 2010 Jan; 46: 160-169
        • Langseth Ø.O.
        • Myklebust T.Å.
        • Johannesen T.B.
        • et al.
        Incidence and survival of multiple myeloma: a population-based study of 10 524 patients diagnosed 1982–2017.
        Br J Haematol. 2020; (2020/05/05;n/a(n/a)) (Epub ahead of print)
        • Fakhri B.
        • Fiala M.A.
        • Tuchman S.A.
        • et al.
        Undertreatment of older patients with newly diagnosed multiple myeloma in the era of novel therapies.
        Clin Lymphoma Myeloma Leuk. 2018 Mar; 18: 219-224
        • Costa L.J.
        • Huang J.X.
        • Hari P.N.
        Disparities in utilization of autologous hematopoietic cell transplantation for treatment of multiple myeloma.
        Biol Blood Marrow Transplant. 2015 Apr; 21: 701-706
        • Costa L.J.
        • Gonsalves W.I.
        • Kumar S.K.
        Early mortality in multiple myeloma.
        Leukemia. 2015 Jul; 29: 1616-1618
        • Kumar S.K.
        • Dispenzieri A.
        • Lacy M.Q.
        • et al.
        Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients.
        Leukemia. 2014 May; 28: 1122-1128
        • Silver S.A.
        • Harel Z.
        • McArthur E.
        • et al.
        Causes of death after a hospitalization with AKI.
        J Am Soc Nephrol. 2018 Mar; 29: 1001-1010
      2. Program in Evidence Based Care-Cancer Care Ontario, Accessed March 25, 2020

        • Fiala M.A.
        • Dukeman J.
        • Tuchman S.A.
        • et al.
        Development of an algorithm to distinguish smoldering versus symptomatic multiple myeloma in claims-based data sets.
        JCO Clin Cancer Inform. 2017; 1
        • Deyo R.A.
        • Cherkin D.C.
        • Ciol M.A.
        Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases.
        J Clin Epidemiol. 1992 Jun; 45: 613-619
        • Kralj B.
        Measuring Rurality - RIO2008_BASIC: Methodology and Results.
        Ontario Medical Association Economics Department, 2009
        • Matheson F.I.
        • White H.L.
        • Moineddin R.
        • et al.
        Neighbourhood chronic stress and gender inequalities in hypertension among Canadian adults: a multilevel analysis.
        J Epidemiol Community Health. 2010; 64: 705-713
        • Fiala M.A.
        • Foley N.C.
        • Zweegman S.
        • et al.
        The characteristics, treatment patterns, and outcomes of older adults aged 80 and over with multiple myeloma.
        J Geriatr Oncol. 2020; (10:S1879-4068(19)30393-5) (2020/03/10/) (Epub ahead of print)
        • Olszewski A.J.
        • Shrestha R.
        • Castillo J.J.
        Treatment selection and outcomes in early-stage classical Hodgkin lymphoma: analysis of the National Cancer Data Base.
        J Clin Oncol. 2015 Feb 20; 33: 625-633
        • Rose T.L.
        • Deal A.M.
        • Nielsen M.E.
        • et al.
        Sex disparities in use of chemotherapy and survival in patients with advanced bladder cancer.
        Cancer. 2016; 122: 2012-2020
        • Warren J.L.
        • Harlan L.C.
        • Stevens J.
        • et al.
        Multiple myeloma treatment transformed: a population-based study of changes in initial management approaches in the United States.
        J Clin Oncol. 2013 Jun 1; 31: 1984-1989
        • Lublóy Á.
        Factors affecting the uptake of new medicines: a systematic literature review.
        BMC Health Serv Res. 2014; 14: 469
        • Fiala M.A.
        • Vij R.
        • Wildes T.M.
        A mixed-methods study of stem cell transplantation utilization for newly diagnosed multiple myeloma.
        Clin Lymphoma Myeloma Leuk. 2019 Sep; 19: e521-e525
        • Mina R.
        • Bringhen S.
        • Wildes T.M.
        • et al.
        Approach to the older adult with multiple myeloma.
        39. American Society of Clinical Oncology Educational Book, 2019: 500-518 (2019/05/01)
        • Moreau P.
        • San Miguel J.
        • Sonneveld P.
        • et al.
        Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
        Ann Oncol. 2017 Jul 1; 28 (iv52-iv61)
        • Kumar S.K.
        • Callander N.S.
        • Hillengass J.
        • et al.
        NCCN guidelines insights: multiple myeloma, version 1.2020.
        J Natl Compr Canc Netw. 2019 Oct 1; 17: 1154-1165
        • Merz M.
        • Jansen L.
        • Castro F.A.
        • et al.
        Survival of elderly patients with multiple myeloma-effect of upfront autologous stem cell transplantation.
        Eur J Cancer. 2016 Jul; 62: 1-8
        • Blimark C.H.
        • Turesson I.
        • Genell A.
        • et al.
        Outcome and survival of myeloma patients diagnosed 2008-2015. Real-world data on 4904 patients from the Swedish myeloma registry.
        Haematologica. 2018 Mar; 103: 506-513
        • Ailawadhi S.
        • Parikh K.
        • Abouzaid S.
        • et al.
        Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: a SEER-Medicare analysis.
        Blood Adv. 2019 Oct 22; 3: 2986-2994
        • Mikhael J.
        • Ismaila N.
        • Cheung M.C.
        • et al.
        Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline.
        J Clin Oncol. 2019 May 10; 37: 1228-1263
        • Wildes T.M.
        • Anderson K.C.
        Approach to the treatment of the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a US hematologist and a geriatric hematologist.
        Hematology Am Soc Hematol Educ Program. 2018; 2018: 88-96
        • Duma N.
        • Azam T.
        • Riaz I.B.
        • et al.
        Representation of minorities and elderly patients in multiple myeloma clinical trials.
        Oncologist. 2018; 23: 1076-1078
        • Zulman DM
        • Sussman JB
        • Chen X
        • et al.
        Examining the evidence: a systematic review of the inclusion and analysis of older adults in randomized controlled trials.
        J Gen Intern Med. 2011 Jul; 26: 783-790
        • Chari A.
        • Romanus D.
        • Palumbo A.
        • Blazer M.
        • Farrelly E.
        • Raju A.
        • Huang H.
        • Richardson P.
        Randomized Clinical Trial Representativeness and Outcomes in Real-World Patients: Comparison of 6 Hallmark Randomized Clinical Trials of Relapsed/Refractory Multiple Myeloma.
        Clin Lymphoma Myeloma Leuk. 2020 Jan; 20 (8-17.e16. Epub 2019 Oct 10. PMID: 31722839)
        • Fiala M.A.
        • Wildes T.M.
        Racial disparities in treatment use for multiple myeloma.
        Cancer. 2017 May 1; 123: 1590-1596
        • Palumbo A.
        • Bringhen S.
        • Mateos M.-V.
        • et al.
        Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an international myeloma working group report.
        Blood. 2015; 125: 2068-2074
        • Pawlyn C.
        • Cairns D.
        • Kaiser M.
        • et al.
        The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial.
        Leukemia. 2020; 34 (2020/02/01): 604-612
        • Rajkumar S.V.
        • Dimopoulos M.A.
        • Palumbo A.
        • et al.
        International myeloma working group updated criteria for the diagnosis of multiple myeloma.
        Lancet Oncol. 2014 Nov; 15: e538-e548
        • Mohile S.G.
        • Epstein R.M.
        • Hurria A.
        • et al.
        Communication with older patients with cancer using geriatric assessment: a cluster-randomized clinical trial from the National Cancer Institute community oncology research program.
        JAMA Oncol. 2020; 6: 196-204
        • Cairns D.
        • Pawlyn C.
        • Royle K.-L.
        • et al.
        Frailty-adjusted therapy in transplant non-eligible patients with newly diagnosed multiple myeloma (FiTNEss): a UK myeloma research Alliance study, myeloma XIV.
        Blood. 2019; 134: 3153